Inhibition of FAK kinase activity preferentially targets cancer stem cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Vihren N. Kolev 1 , Winnie F. Tam 1 , Quentin G. Wright 1 , Sean P. McDermott 2 , Christian M. Vidal 1 , Irina M. Shapiro 1 , Qunli Xu 1 , Max S. Wicha 2 , Jonathan A. Pachter 1 and David T. Weaver 1 1 Verastem, Inc., Needham, MA, USA 2 Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA Correspondence to: David T. Weaver, email: dweaver@verastem.com Jonathan A. Pachter, email: jpachter@verastem.com Keywords: cancer stem cells, FAK, focal adhesion kinase, VS-4718, VS-6063 Received: February 02, 2017 Accepted: May 06, 2017 Published: June 16, 2017 ABSTRACT Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting of CSCs holds promise to address these clinical challenges to cancer treatment. VS-4718 and VS-6063 are potent inhibitors of focal adhesion kinase (FAK), a non-receptor tyrosine kinase that mediates cell signals transmitted by integrins and growth factor receptors. We report here that inhibition of FAK kinase activity by VS-4718 or VS-6063 preferentially targets CSCs, as demonstrated by a panel of orthogonal CSC assays in cell line models and surgically resected primary breast tumor specimens cultured ex vivo . Oral administration of VS-4718 or VS-6063 to mice bearing xenograft models of triple-negative breast cancer (TNBC) significantly reduced the proportion of CSCs in the tumors, as evidenced by a reduced tumor-initiating capability upon re-implantation in limiting dilutions of cells prepared from these tumors. In contrast, the cytotoxic chemotherapeutic agents, paclitaxel and carboplatin, enriched for CSCs, consistent with previous reports that these cytotoxic agents preferentially target non-CSCs. Importantly, VS-4718 and VS-6063 attenuated the chemotherapy-induced enrichment of CSCs in vitro and delayed tumor regrowth following cessation of chemotherapy. An intriguing crosstalk between FAK and the Wnt/β-catenin pathway was revealed wherein FAK inhibition blocks β-catenin activation by reducing tyrosine 654 phosphorylation of β-catenin. Furthermore, a constitutively active mutant form of β-catenin reversed the preferential targeting of CSCs by FAK inhibition, suggesting that this targeting is mediated, at least in part, through attenuating β-catenin activation. The preferential targeting of cancer stem cells by FAK inhibitors provides a rationale for the clinical development of FAK inhibitors aimed to increase durable responses for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FAK in cancer: mechanistic findings and clinical applications
Sulzmaier, F. J., Jean, C., & Schlaepfer, D. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3792 · Cited by 1,381 · cited 1×
“Indeed, several small molecule FAK kinase inhibitors have been shown to decrease tumor growth and metastasis in preclinical models and advanced to clinical development [18, 19].”
BackgroundCdc42 regulates GSK-3β and adenomatous polyposis coli to control cell polarity
Etienne-Manneville, S., & Hall, A. (2003) · Nature · doi:10.1038/nature01423 · Cited by 835
Hirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., & Sahai, E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.008 · Cited by 593
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Serrels, A., Lund, T., Serrels, B., Byron, A., McPherson, R. C., von Kriegsheim, A., Gómez-Cuadrado, L., Canel, M., Muir, M., Ring, J. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.001 · Cited by 407 · cited 1×
“Furthermore, FAK inhibition has also been shown to induce T cell-mediated tumor regression and enhance the efficacy of immune checkpoint inhibitors [22, 23].”
BackgroundSelf-citationFrame, M. C., & Serrels, A. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.013 · Cited by 23
Cited by
Fibrosis and cancer: A strained relationship
Piersma, B., Hayward, M.-K., & Weaver, V. M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188356 · Cited by 680
Liu, X., Taftaf, R., Kawaguchi, M., Chang, Y.-F., Chen, W., Entenberg, D., Zhang, Y., Gerratana, L., Huang, S., Patel, D. B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0065 · Cited by 390
Targeting FAK in anticancer combination therapies
Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D., & Frame, M. C. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00340-6 · Cited by 384
Focal adhesion kinase: from biological functions to therapeutic strategies
Tan, X., Yan, Y., Song, B., Zhu, S., Mei, Q., & Wu, K. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00446-7 · Cited by 158
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
Diaz Osterman, C. J., Ozmadenci, D., Kleinschmidt, E. G., Taylor, K. N., Barrie, A. M., Jiang, S., Bean, L. M., Sulzmaier, F. J., Jean, C., Tancioni, I., et al. (2019) · eLife · doi:10.7554/elife.47327 · Cited by 145
Self-citation
Metadata
- Authors
- Kolev, V. N., Tam, W. F., Wright, Q. G., McDermott, S. P., Vidal, C. M., Shapiro, I. M., Xu, Q., Wicha, M. S., Pachter, J. A., & Weaver, D. T.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-06-16
- Volume
- 8
- Issue
- 31
- Pages
- 51733-51747
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2626577233
- Cited by
- 73
- References
- 5
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of FAK kinase activity preferentially targets cancer stem cells. https://app.cochat.ai/papers/10.18632/oncotarget.18517
- The paper
- Kolev, V. N., Tam, W. F., Wright, Q. G., McDermott, S. P., Vidal, C. M., Shapiro, I. M., Xu, Q., Wicha, M. S., Pachter, J. A., & Weaver, D. T. (2017). Inhibition of FAK kinase activity preferentially targets cancer stem cells. Oncotarget. https://doi.org/10.18632/oncotarget.18517
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.